Skip to content

Oncotelic Therapeutics, Inc.: current accounts payable

Oncotelic Therapeutics current accounts payable: $1.74 million at 2022-12-31, down 10.0% on the year. 13 values since 2010, each linked to its SEC filing.

All Oncotelic Therapeutics, Inc. financial histories

At a glance

Oncotelic Therapeutics reported current accounts payable of $1.74 million at 2022-12-31, down 10.0% from $1.93 million a year earlier. From 2010 to 2022 it grew at a compound 11.7% a year, from $458.0 thousand to $1.74 million. Across the last five reported years it ranged from $915.0 thousand (2018-12-31) to $1.94 million (2020-12-31). That was 4.8% of total assets ($36.1 million) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Exact concept: us-gaap:AccountsPayableCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2022-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Current accounts payable in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2022-12-311,735,764USD2023-04-2010-K/A · 0001493152-23-012978 SEC
-2021-12-311,927,749USD2023-04-2010-K/A · 0001493152-23-012978 SEC
-2020-12-311,937,419USD2022-04-1510-K · 0001493152-22-010094 SEC
-2019-12-311,793,033USD2021-04-1510-K · 0001493152-21-008920 SEC
-2018-12-31915,000USD2019-04-1010-K · 0001193125-19-102832 SEC
-2017-12-31788,000USD2019-04-1010-K · 0001193125-19-102832 SEC
-2016-12-31310,000USD2018-04-1710-K · 0001193125-18-119206 SEC
-2015-12-31287,000USD2017-03-3010-K · 0001193125-17-103621 SEC
-2014-12-31335,000USD2016-03-2510-K · 0001193125-16-518083 SEC
-2013-12-31476,000USD2015-03-3010-K · 0001193125-15-111261 SEC
-2012-12-31416,000USD2014-03-2010-K · 0001193125-14-108092 SEC
-2011-12-31261,000USD2013-03-1510-K · 0001193125-13-110175 SEC
-2010-12-31458,000USD2012-03-2810-K · 0001193125-12-137327 SEC

Related Oncotelic Therapeutics, Inc. histories

All 47 Oncotelic Therapeutics histories

Inspect the source

Entity
Oncotelic Therapeutics, Inc. / CIK 0000908259
Captured
SEC response SHA-256
6c0026f9e455c874f284117994b59a028bad3a82bccf268424724837d8c3b9db

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000908259.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))